Vi­vo Cap­i­tal, Bain, Pri­mav­era pour $200M in­to vir­tu­al­ly un­known tar­get­ed on­col­o­gy play out of Chi­na

Hong­bo Lu was a board mem­ber at Crown­Bio, a pre­clin­i­cal on­col­o­gy CRO, when a lo­cal com­pa­ny — so lo­cal it didn’t even have an Eng­lish name — li­censed a c-Met in­hibitor from them. Then they didn’t think much about it.

Over the next eight years though, Lu, a part­ner at Vi­vo Cap­i­tal, watched the biotech boot­strap it­self, build­ing a whole pipeline and dis­cov­ery ca­pa­bil­i­ties around the an­chor­ing as­set.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER